In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling; In silico pharmacology for drug discovery: applications to targets and beyond; Exploiting machine learning for end-to-end drug discovery and development; Progress in predicting human ADME parameters in silico; Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel; Pathway mapping tools for analysis of high content data; Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites; In silico repositioning of approved drugs for rare and neglected diseases; Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery data sets; Present and future in vitro approaches for drug metabolism; Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates; Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity; Design, synthesis, cytoselective toxicity, structureâ€“activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells; Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein; The role of CYP2B6 in human xenobiotic metabolism; The next era: deep learning in pharmaceutical research; Further characterization of the expression in liver and catalytic activity of CYP2B6; A pharmacophore for human pregnane X receptor ligands; In vitro and pharmacophore insights into CYP3A enzymes; Three-and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors
